Compare VNDA & MBVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VNDA | MBVI |
|---|---|---|
| Founded | 2002 | 2025 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 441.5M | 433.0M |
| IPO Year | 2006 | 2025 |
| Metric | VNDA | MBVI |
|---|---|---|
| Price | $8.10 | $10.13 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $13.63 | N/A |
| AVG Volume (30 Days) | ★ 2.8M | 88.6K |
| Earning Date | 02-12-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $212,074,000.00 | N/A |
| Revenue This Year | $12.01 | N/A |
| Revenue Next Year | $24.28 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 11.12 | N/A |
| 52 Week Low | $3.81 | $9.99 |
| 52 Week High | $9.60 | $10.50 |
| Indicator | VNDA | MBVI |
|---|---|---|
| Relative Strength Index (RSI) | 61.30 | N/A |
| Support Level | $7.14 | N/A |
| Resistance Level | $7.82 | N/A |
| Average True Range (ATR) | 0.44 | 0.00 |
| MACD | -0.05 | 0.00 |
| Stochastic Oscillator | 62.09 | 0.00 |
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.
M3-Brigade Acquisition VI Corp is a newly incorporated blank check company.